ResMed showed 29% EPS growth last quarter. Sales gains came in at 10%. ResMed earns the No. 6 rank among its peers in the ...

ResMed has grown into a company that specialises in non-invasive technology solutions that improve sleep health worldwide.

StockNews.com cut shares of ResMed (NYSE:RMD – Free Report) from a buy rating to a hold rating in a research note published on Friday morning. Several other equities analysts have also issued reports ...

In my previous article, we advocated that ResMed's products are in high demand, even with the challenges from various state-of-the-art weight loss drugs, such as Zepbound. And we would like to ...

and as home healthcare customers request ResMed products--especially masks and pillows--this highly profitable recurring revenue stream helps endear ResMed to its customer base. ResMed faces tough ...

Although these are interchangeable with other brands, competitors would be challenged to offer original products that are comparable in quality and comfort without infringing on ResMed’s ...

ResMed has beaten its earnings forecast in the second quarter despite concerns from investors around weight loss drugs impacting the necessity for sleep device products. ResMed’s revenue jumped ...

The great quarter was driven by high demand for sleep-related products and growth in digital health solutions. As a specialist in sleep and respiratory health, ResMed built its reputation through ...

RMD outperforms the industry and the S&P 500 composite due to its success with the cloud-connected AirSense platform.

Stock price declined 6.6% in after-hours trading despite strong earnings. ResMed launched new products and expanded its digital health solutions. The company maintained a robust cash flow and ...

ResMed's EPS and revenue exceeded forecasts for Q2 FY2025. Stock price declined 6.6% in after-hours trading despite strong earnings. ResMed launched new products and expanded its digital health ...